FY2026 Earnings Forecast for Haemonetics Co. Issued By Barrington Research (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Analysts at Barrington Research decreased their FY2026 earnings per share estimates for shares of Haemonetics in a research report issued on Friday, April 12th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will earn $4.80 per share for the year, down from their previous forecast of $4.85. Barrington Research has a “Outperform” rating and a $105.00 price objective on the stock. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Barrington Research also issued estimates for Haemonetics’ FY2027 earnings at $5.52 EPS.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. During the same period in the prior year, the company posted $0.85 earnings per share. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year.

A number of other research analysts have also weighed in on HAE. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.

Haemonetics Stock Performance

NYSE HAE opened at $84.21 on Monday. The business’s 50-day moving average price is $78.56 and its 200 day moving average price is $82.76. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The firm has a market cap of $4.28 billion, a P/E ratio of 34.23, a P/E/G ratio of 2.01 and a beta of 0.36. Haemonetics has a 52-week low of $70.74 and a 52-week high of $95.26.

Institutional Investors Weigh In On Haemonetics

Several institutional investors have recently bought and sold shares of HAE. Meeder Asset Management Inc. boosted its stake in shares of Haemonetics by 65.2% in the fourth quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 135 shares during the period. State of Wyoming acquired a new stake in shares of Haemonetics during the fourth quarter valued at about $28,000. Carmel Capital Partners LLC acquired a new stake in shares of Haemonetics during the third quarter valued at about $30,000. Belpointe Asset Management LLC increased its position in shares of Haemonetics by 65.5% during the first quarter. Belpointe Asset Management LLC now owns 455 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 180 shares during the last quarter. Finally, AdvisorNet Financial Inc lifted its stake in shares of Haemonetics by 3,963.6% in the third quarter. AdvisorNet Financial Inc now owns 447 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 436 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.